Little is known about the natural history of epidermal growth factor receptor (
EGFR)
-mutated non-small-cell lung cancer (NSCLC) in Caucasian patients treated with surgery before the generalization of adjuvant treatment with osimertinib.
The primary objective of this study was to describe the outcomes...
J. Auliac, P. Thomas, O. Bylicki et al.· Therapeutic Advances in Medi...· 0 citations
BACKGROUND
Pembrolizumab, alone or combined with platinum-based chemotherapy, is a standard first-line treatment for patients with metastatic non-small-cell lung cancer (NSCLC) without actionable oncogenic alterations and with high programmed death-ligand 1 (PD-L1) expression. We conducted a head-to-head comparison of...
R. Descourt, A. Mogenet, Maelys Consigny et al.· Annals of Oncology· 0 citations
This study showed no OS gain in second-line treatment among patients pretreated with immunotherapy compared with those who received chemotherapy alone as first-line treatment.
E. Gobbini, M. H. Diallo, C. Clément-Duchêne et al.· ESMO Open· 0 citations
Simple Summary In patients with advanced lung cancer harboring targetable gene mutations, sequential immunotherapy-targeted therapy was associated with higher rate of adverse events. A short delay between last immunotherapy administration and targeted therapy administration may increase the risk of serious adverse even...
Thomas Pierret, J. Auliac, C. Ricordel et al.· Current Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.